TNGX Tango Therapeutics, Inc.
$22.23▼ -2.88%
Healthcare
Other
After hours
$22.27▲ +0.18%
Oct 28, 6:15 PM ET
Volume 3.31M
Avg Volume (10D) 5.06M
Key Metrics & Fundamentals
Market Cap
$3.75B
P/E Ratio
–
Div Yield
0.00%
52W Range
7.37 - 34.39
% vs 50 MA
-6.10%
% vs 200 MA
0.06%
RSI-14
44.8
MACD Histogram
-0.0900
Beta (1Y vs SPY)
1.38
Free Cash Flow
-$38.87M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$59.36M
COGS
–
Operating Exp
$59.79M
Operating Income
-$59.79M
EBIT
-$59.79M
Pretax Income
-$55.34M
Net Income
-$55.34M
EPS (Diluted)
-0.37
Price & Volume History
Loading chart…
Recent News
Tango Therapeutics (TNGX) Following Trial Update Has Its Valuation Story Back In Focus
Simply Wall St. · Oct 28, 2026 1:11 PM ET
Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside?
Insider Monkey · Oct 28, 2026 9:16 AM ET
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
Zacks · Oct 26, 2026 10:41 AM ET
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug
Investor's Business Daily · Oct 23, 2026 4:06 PM ET
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate
MarketBeat · Oct 23, 2026 12:06 PM ET
Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?
Benzinga · Oct 23, 2026 11:36 AM ET
Tango Therapeutics Sinks 13% on Pancreatic Cancer Data It Says “Surpass Any Published PDAC Datasets”
TIKR · Oct 23, 2026 10:59 AM ET
Wedbush Adjusts Price Target on Tango Therapeutics to $45 From $39, Maintains Outperform Rating
MT Newswires · Oct 23, 2026 10:35 AM ET
Tango Therapeutics stock falls despite positive cancer trial data
Investing.com · Oct 23, 2026 8:04 AM ET
Tango Therapeutics Reports 82% Response Rate in Pancreatic Cancer Trial
MT Newswires · Oct 23, 2026 7:19 AM ET
Financial Overview - Income Statement
Quarterly
Sep 2025
See TNGX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.